“Question: Are COVID-19 vaccines associated with Guillain-Barré syndrome (GBS)?
Findings: In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence rate of confirmed GBS in the 1 to 21 days after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years, which was significantly higher than the background rate of GBS. The unadjusted incidence rate of confirmed GBS in the 1 to 21 days after mRNA vaccines was 1.3 per 100 000 person-years, which did not differ from the background rate.
Meaning: These findings suggest an increased risk of GBS after Ad.26.COV2.S vaccination.”
This is an open access article distributed under the terms of the CC-BY License.